<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pulmo</journal-id><journal-title-group><journal-title xml:lang="ru">Пульмонология</journal-title><trans-title-group xml:lang="en"><trans-title>PULMONOLOGIYA</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0189</issn><issn pub-type="epub">2541-9617</issn><publisher><publisher-name>Scientific and Practical Journal “PULMONOLOGIYA” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18093/0869-0189-2016-26-3-267-291</article-id><article-id custom-type="elpub" pub-id-type="custom">pulmo-717</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GUIDELINES</subject></subj-group></article-categories><title-group><article-title>Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 2-я)</article-title><trans-title-group xml:lang="en"><trans-title>Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>статья</surname><given-names>Редакционная</given-names></name><name name-style="western" xml:lang="en"><surname>Article</surname><given-names>Editorial</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>27</day><month>07</month><year>2016</year></pub-date><volume>26</volume><issue>3</issue><fpage>267</fpage><lpage>291</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; статья Р., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">статья Р.</copyright-holder><copyright-holder xml:lang="en">article E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.pulmonology.ru/pulm/article/view/717">https://journal.pulmonology.ru/pulm/article/view/717</self-uri><abstract><p>Хроническая обструктивная болезнь легких (ХОБЛ) является одной из основных причин заболеваемости и летальности в США и в мире. Обострения ХОБЛ (периодическое усиление кашля, одышки и продукции мокроты) вносят серьезный вклад в снижение легочной функции, качества жизни, повышение потребности в неотложной помощи и госпитализациях, а также в стоимость лечения больных. В последние десятилетия выполнены исследования, по результатам которых существенно углубилось понимание патогенеза ХОБЛ и расширились терапевтические возможности. Накоплен также большой объем публикаций по предотвращению обострений ХОБЛ.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Для разъяснения важности предотвращения обострений ХОБЛ Американской коллегией торакальных врачей (American College of Chest Physicians – CHEST) и Канадским торакальным обществом (Canadian Thoracic Society Guideline – CTS) разработаны совместные Клинические рекомендации, в которых описан существующий сегодня подход к профилактике обострений ХОБЛ. Выделены 3 основных клинических проблемы профилактики обострений ХОБЛ на основе принципов PICO (Population, Intervention, Comparator, Outcome – Популяция, Вмешательства, Сравнение, Исходы) – немедикаментозное лечение, ингаляционная и пероральная терапия. Использована общепринятая система отбора соответствующих клинических исследований и оценки класса рекомендаций.</p></sec><sec><title>Результаты</title><p>Результаты. Особенность Клинических рекомендаций по профилактике обострений ХОБЛ заключается не только в их тематике, но также в том, что они стали первым результатом сотрудничества 2 крупных торакальных обществ Северной Америки. Намерение Надзорного комитета по созданию клинических рекомендаций CHEST в сотрудничестве с Клинической ассамблеей по ХОБЛ CTS заключается в том, чтобы на основе систематического обзора и критической оценки опубликованной литературы, сделанных клиническими экспертами и исследователями в области ХОБЛ, разработать клинические рекомендации с целью помочь клиницистам в ведении пациентов с этим заболеванием.</p></sec><sec><title>Заключение</title><p>Заключение. В данных Рекомендациях содержится современный доказательный анализ опубликованных результатов рандомизированных контролируемых исследований по профилактике обострений ХОБЛ.</p></sec></abstract><trans-abstract xml:lang="en"><p>Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality worldwide. An acute exacerbation of COPD greatly contributes to worsening lung function, impairment in quality of life, need for urgent care, and use of medical utilities. Last decade, our understanding of the pathogenesis and treatment of COPD has significantly improved. The guideline accumulated recent information about the prevention of acute exacerbations of COPD.</p><sec><title>Methods</title><p>Methods. The American College of Chest Physicians and Canadian Thoracic Society developed evidencebased guideline to describe the current knowledge on the prevention of acute exacerbations in a clinically useful manner. The PICO approach (population, intervention, comparator, and outcome) was used which involved nonpharmacologic therapies, inhaled therapies, and oral therapies. To select the most appropriate studies, to extract evidencebased data and to grade the level of evidence, evidencebased document assessment tools were applied.</p></sec><sec><title>Results</title><p>Results. The guideline was designed as a systematic review and critical evaluation of the published literature by clinical experts and researchers in the field of COPD and recommendations were developed to help clinicians in their management of the patient with COPD.</p></sec><sec><title>Conclusion</title><p>Conclusion. This guideline provides an uptodate, rigorous, evidencebased analysis of current randomized controlled trials on the prevention of COPD exacerbations.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>обострения</kwd><kwd>доказательная медицина</kwd><kwd>клинические рекомендации.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>exacerbations</kwd><kwd>evidencebased document</kwd><kwd>guideline</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2103. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd. org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed May 15, 2014.</mixed-citation><mixed-citation xml:lang="en">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2103. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd. org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed May 15, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur. Respir. Rev. 2006; 15 (99): 32–36.</mixed-citation><mixed-citation xml:lang="en">Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur. Respir. Rev. 2006; 15 (99): 32–36.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper C.B. Airflow obstruction and exercise. Respir. Med. 2009; 103 (3): 325–334.</mixed-citation><mixed-citation xml:lang="en">Cooper C.B. Airflow obstruction and exercise. Respir. Med. 2009; 103 (3): 325–334.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Public Health Agency of Canada. Chronic obstructive pulmonary disease (COPD). Public Health Agency of Canada website. http://www.phac#aspc.gc.ca/cd#mc/crd#mrc/copdmpoc#eng.php. Accessed June 28, 2012.</mixed-citation><mixed-citation xml:lang="en">Public Health Agency of Canada. Chronic obstructive pulmonary disease (COPD). Public Health Agency of Canada website. http://www.phac#aspc.gc.ca/cd#mc/crd#mrc/copdmpoc#eng.php. Accessed June 28, 2012.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: final data for 2009. Natl. Vital. Stat. Rep. 2012; 60 (3): 1–117.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: final data for 2009. Natl. Vital. Stat. Rep. 2012; 60 (3): 1–117.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention; National Center for Health Statistics. National Health Interview Survey Raw Data, 1999–2011. Analysis performed by the American Lung Association Research and Healtheducation Division using SPSS and SUDAAN software. Atlanta GA: Centers for Disease Control and Prevention; 2011.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention; National Center for Health Statistics. National Health Interview Survey Raw Data, 1999–2011. Analysis performed by the American Lung Association Research and Healtheducation Division using SPSS and SUDAAN software. Atlanta GA: Centers for Disease Control and Prevention; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mannino D.M., Homa D.M., Akinbami L.J. et al. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51 (6): 1–16.</mixed-citation><mixed-citation xml:lang="en">Mannino D.M., Homa D.M., Akinbami L.J. et al. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51 (6): 1–16.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention; National Center for Health Statistics. National Hospital Discharge Survey Raw Data, 1999–2010. Analysis Performed by the American Lung Association Research and Healtheducation Division Using SPSS Soft ware. Atlanta GA: Centers for Disease Control and Prevention; 2010.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention; National Center for Health Statistics. National Hospital Discharge Survey Raw Data, 1999–2010. Analysis Performed by the American Lung Association Research and Healtheducation Division Using SPSS Soft ware. Atlanta GA: Centers for Disease Control and Prevention; 2010.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Confronting COPD in America, 2000. Schulman, Ronca and Bucuvalas, Inc. (SRBI); 2000. Funded by Glaxo SmithKline plc.</mixed-citation><mixed-citation xml:lang="en">Confronting COPD in America, 2000. Schulman, Ronca and Bucuvalas, Inc. (SRBI); 2000. Funded by Glaxo SmithKline plc.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mittmann N., Kuramoto L., Seung S.J. et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir. Med. 2008; 102 (3): 413–421.</mixed-citation><mixed-citation xml:lang="en">Mittmann N., Kuramoto L., Seung S.J. et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir. Med. 2008; 102 (3): 413–421.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chapman K.R., Bourbeau J., Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S23–S31.</mixed-citation><mixed-citation xml:lang="en">Chapman K.R., Bourbeau J., Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S23–S31.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154 (4): 959–967.</mixed-citation><mixed-citation xml:lang="en">Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154 (4): 959–967.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5): 1418–1422.</mixed-citation><mixed-citation xml:lang="en">Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5): 1418–1422.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455.</mixed-citation><mixed-citation xml:lang="en">Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Miravitlles M., García"Polo C., Domenech A. et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013; 191 (5): 523–530.</mixed-citation><mixed-citation xml:lang="en">Miravitlles M., García"Polo C., Domenech A. et al. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013; 191 (5): 523–530.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wouters E.F. Economic analysis of the confronting COPD survey: an overview of results. Respir. Med. 2003; 97 (Suppl. C): S3–S14.</mixed-citation><mixed-citation xml:lang="en">Wouters E.F. Economic analysis of the confronting COPD survey: an overview of results. Respir. Med. 2003; 97 (Suppl. C): S3–S14.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.</mixed-citation><mixed-citation xml:lang="en">Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Maltais F., Celli B., Casaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105 (4): 580–587.</mixed-citation><mixed-citation xml:lang="en">Maltais F., Celli B., Casaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105 (4): 580–587.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez"Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000; 117 (5, Suppl. 2): 398S–401S.</mixed-citation><mixed-citation xml:lang="en">Rodriguez"Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000; 117 (5, Suppl. 2): 398S–401S.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155 (3):179–191.</mixed-citation><mixed-citation xml:lang="en">Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155 (3):179–191.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Albert R.K., Connett J., Bailey W.C. et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365 (8): 689–698.</mixed-citation><mixed-citation xml:lang="en">Albert R.K., Connett J., Bailey W.C. et al. COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365 (8): 689–698.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 (9356): 449–456.</mixed-citation><mixed-citation xml:lang="en">Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 (9356): 449–456.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Tashkin D.P., Celli B., Senn S. et al; UPLIFT Study Investigators. A 4"year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.</mixed-citation><mixed-citation xml:lang="en">Tashkin D.P., Celli B., Senn S. et al; UPLIFT Study Investigators. A 4"year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis S.Z., Diekemper R., Ornelas J., Casey K.R. Methodologies for the development of CHEST guidelines and expert panel reports. Chest. 2014; 146 (1): 182–192.</mixed-citation><mixed-citation xml:lang="en">Lewis S.Z., Diekemper R., Ornelas J., Casey K.R. Methodologies for the development of CHEST guidelines and expert panel reports. Chest. 2014; 146 (1): 182–192.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers M.C., Kho M.E., Browman G.P. et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182 (18): E839–E842.</mixed-citation><mixed-citation xml:lang="en">Brouwers M.C., Kho M.E., Browman G.P. et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182 (18): E839–E842.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Diekemper R., Ireland B., Merz L. P154 development of the Documentation and Appraisal Review Tool (DART) for systematic reviews [poster]. Br. Med. J. Qual. Saf. 2013; 22: 61–62.</mixed-citation><mixed-citation xml:lang="en">Diekemper R., Ireland B., Merz L. P154 development of the Documentation and Appraisal Review Tool (DART) for systematic reviews [poster]. Br. Med. J. Qual. Saf. 2013; 22: 61–62.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Higgins J.P.T., Altman D.G., Sterne J.A.C. et al. Chapter 8: assessing risk of bias in included studies. In: Higgins J.P.T., Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration; 2011.</mixed-citation><mixed-citation xml:lang="en">Higgins J.P.T., Altman D.G., Sterne J.A.C. et al. Chapter 8: assessing risk of bias in included studies. In: Higgins J.P.T., Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. London: The Cochrane Collaboration; 2011.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non"randomised studies of health care interventions. J. Epidemiol. Community Health. 1998; 52 (6): 377–384.</mixed-citation><mixed-citation xml:lang="en">Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non"randomised studies of health care interventions. J. Epidemiol. Community Health. 1998; 52 (6): 377–384.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Langer"Gould A., Popat R.A., Huang S.M. et al. Clinical and demographic predictors of long"term disability in patients with relapsing"remitting multiple sclerosis: a systematic review. Arch. Neurol. 2006; 63 (12): 1686–1691.</mixed-citation><mixed-citation xml:lang="en">Langer"Gould A., Popat R.A., Huang S.M. et al. Clinical and demographic predictors of long"term disability in patients with relapsing"remitting multiple sclerosis: a systematic review. Arch. Neurol. 2006; 63 (12): 1686–1691.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Aaron S.D., Fergusson D., Marks G.B. et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008; 63 (2): 122–128.</mixed-citation><mixed-citation xml:lang="en">Aaron S.D., Fergusson D., Marks G.B. et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008; 63 (2): 122–128.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Balshem H., Helfand M., Schünemann H.J. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 2011; 64 (4): 401–406.</mixed-citation><mixed-citation xml:lang="en">Balshem H., Helfand M., Schünemann H.J. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 2011; 64 (4): 401–406.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt G., Gutterman D., Baumann M.H. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006; 129 (1): 174–181.</mixed-citation><mixed-citation xml:lang="en">Guyatt G., Gutterman D., Baumann M.H. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006; 129 (1): 174–181.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Graham I.D., Logan J., Harrison M.B. et al. Lost in knowledge translation: time for a map? J. Contin. Educ. Health Prof. 2006; 26 (1): 13–24.</mixed-citation><mixed-citation xml:lang="en">Graham I.D., Logan J., Harrison M.B. et al. Lost in knowledge translation: time for a map? J. Contin. Educ. Health Prof. 2006; 26 (1): 13–24.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002; 288 (14): 1775–1779.</mixed-citation><mixed-citation xml:lang="en">Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002; 288 (14): 1775–1779.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002; 288 (15): 1909–1914.</mixed-citation><mixed-citation xml:lang="en">Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002; 288 (15): 1909–1914.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). National Institute for Health and Care Excellence website. http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed May 15, 2014.</mixed-citation><mixed-citation xml:lang="en">Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). National Institute for Health and Care Excellence website. http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed May 15, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">O’Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease"2007 update. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.</mixed-citation><mixed-citation xml:lang="en">O’Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease"2007 update. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Disler R.T., Inglis S.C., Davidson P.M. Non"pharmacological management interventions for COPD: an overview of Cochrane systematic reviews (protocol). Cochrane Database Syst. Rev. 2013; (2): CD010384.</mixed-citation><mixed-citation xml:lang="en">Disler R.T., Inglis S.C., Davidson P.M. Non"pharmacological management interventions for COPD: an overview of Cochrane systematic reviews (protocol). Cochrane Database Syst. Rev. 2013; (2): CD010384.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Kruis A.L., Smidt N., Assendelft W.J.J. et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD009437.</mixed-citation><mixed-citation xml:lang="en">Kruis A.L., Smidt N., Assendelft W.J.J. et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD009437.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Krumholz H.M., Currie P.M., Riegel B. et al. A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006; 114 (13): 1432–1445.</mixed-citation><mixed-citation xml:lang="en">Krumholz H.M., Currie P.M., Riegel B. et al. A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006; 114 (13): 1432–1445.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Craig P., Dieppe P., Macintyre S. et al. Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. Br. Mer. J. 2008; 337: a1655.</mixed-citation><mixed-citation xml:lang="en">Craig P., Dieppe P., Macintyre S. et al. Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. Br. Mer. J. 2008; 337: a1655.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Petticrew M. When are complex interventions ‘complex’? When are simple interventions ‘simple’? Eur. J. Public. Health. 2011; 21 (4): 397–398.</mixed-citation><mixed-citation xml:lang="en">Petticrew M. When are complex interventions ‘complex’? When are simple interventions ‘simple’? Eur. J. Public. Health. 2011; 21 (4): 397–398.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Weightman A., Ellis S., Cullum A. et al. Grading Evidence and Recommendations for Public Health Interventions: Developing and Piloting a Framework. London: Health Development Agency; 2005.</mixed-citation><mixed-citation xml:lang="en">Weightman A., Ellis S., Cullum A. et al. Grading Evidence and Recommendations for Public Health Interventions: Developing and Piloting a Framework. London: Health Development Agency; 2005.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Vaccines and immunizations. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/vpdvac/pneumo. Accessed March 3, 2014.</mixed-citation><mixed-citation xml:lang="en">Vaccines and immunizations. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/vpdvac/pneumo. Accessed March 3, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Lee T.A., Weaver F.M., Weiss K.B. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med. 2007; 22 (1): 62–67.</mixed-citation><mixed-citation xml:lang="en">Lee T.A., Weaver F.M., Weiss K.B. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med. 2007; 22 (1): 62–67.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using 23"valent pneumococcal polysaccharide vaccine (PPSV23). Morb. Mortal. Wkly Rep. 2010; 59 (34): 1102–1106.</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using 23"valent pneumococcal polysaccharide vaccine (PPSV23). Morb. Mortal. Wkly Rep. 2010; 59 (34): 1102–1106.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Bogaert D., van der Valk P., Ramdin R. et al. Hostpathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun. 2004; 72 (2): 818–823.</mixed-citation><mixed-citation xml:lang="en">Bogaert D., van der Valk P., Ramdin R. et al. Hostpathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun. 2004; 72 (2): 818–823.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Patel I.S., Seemungal T.A.R., Wilks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002; 57 (9): 759–764.</mixed-citation><mixed-citation xml:lang="en">Patel I.S., Seemungal T.A.R., Wilks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002; 57 (9): 759–764.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347 (7): 465–471.</mixed-citation><mixed-citation xml:lang="en">Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347 (7): 465–471.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173 (10): 1114–1121.</mixed-citation><mixed-citation xml:lang="en">Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173 (10): 1114–1121.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">WHO recommendations for routine immunization summary tables. World Health Organization website. http://www.who.int/immunization/policy/immunization_tables/en. Accessed March 3, 2014.</mixed-citation><mixed-citation xml:lang="en">WHO recommendations for routine immunization summary tables. World Health Organization website. http://www.who.int/immunization/policy/immunization_tables/en. Accessed March 3, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (11): CD001390.</mixed-citation><mixed-citation xml:lang="en">Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; (11): CD001390.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Dransfield M.T., Harnden S., Burton R.L. al. Long"term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis. 2012; 55 (5): e35–e44.</mixed-citation><mixed-citation xml:lang="en">Dransfield M.T., Harnden S., Burton R.L. al. Long"term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis. 2012; 55 (5): e35–e44.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Furumoto A., Ohkusa Y., Chen M. et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26 (33): 4284–4289.</mixed-citation><mixed-citation xml:lang="en">Furumoto A., Ohkusa Y., Chen M. et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26 (33): 4284–4289.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Fiore A.E., Uyeki T.M., Broder K. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Rec. Rep. 2010; 59 (RR"8): 1– 62.</mixed-citation><mixed-citation xml:lang="en">Fiore A.E., Uyeki T.M., Broder K. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Rec. Rep. 2010; 59 (RR"8): 1– 62.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Centanni S., Pregliasco F., Bonfatti C. et al. Clinical efficacy of a vaccine"immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. J. Chemother. 1997; 9 (4): 273–278.</mixed-citation><mixed-citation xml:lang="en">Centanni S., Pregliasco F., Bonfatti C. et al. Clinical efficacy of a vaccine"immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. J. Chemother. 1997; 9 (4): 273–278.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Monto A.S. Influenza: quantifying morbidity and mortality. Am. J. Med. 1987; 82 (6A): 20–25.</mixed-citation><mixed-citation xml:lang="en">Monto A.S. Influenza: quantifying morbidity and mortality. Am. J. Med. 1987; 82 (6A): 20–25.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Poole P., Chacko E.E., Wood"Baker R., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (1): CD002733.</mixed-citation><mixed-citation xml:lang="en">Poole P., Chacko E.E., Wood"Baker R., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (1): CD002733.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Howells C.H., Tyler L.E. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet. 1961; 278 (7218): 1428–1432.</mixed-citation><mixed-citation xml:lang="en">Howells C.H., Tyler L.E. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet. 1961; 278 (7218): 1428–1432.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Wongsurakiat P., Maranetra K.N., Wasi C. et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004; 125 (6): 2011–2020.</mixed-citation><mixed-citation xml:lang="en">Wongsurakiat P., Maranetra K.N., Wasi C. et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004; 125 (6): 2011–2020.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648.</mixed-citation><mixed-citation xml:lang="en">Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Hersh C.P., DeMeo D.L., Al"Ansari E. et al. Predictors of survival in severe, early onset COPD. Chest. 2004; 126 (5): 1443–1451.</mixed-citation><mixed-citation xml:lang="en">Hersh C.P., DeMeo D.L., Al"Ansari E. et al. Predictors of survival in severe, early onset COPD. Chest. 2004; 126 (5): 1443–1451.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild"to"moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161 (2): 381–390.</mixed-citation><mixed-citation xml:lang="en">Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild"to"moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161 (2): 381–390.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Kanner R.E., Connett J.E., Williams D.E., Buist A.S. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Med. 1999; 106 (4): 410–416.</mixed-citation><mixed-citation xml:lang="en">Kanner R.E., Connett J.E., Williams D.E., Buist A.S. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am. J. Med. 1999; 106 (4): 410–416.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Makris D., Moschandreas J., Damianaki A. et al. Exacerbations and lung function decline in COPD: new insights in current and ex"smokers. Respir. Med. 2007; 101 (6): 1305–1312.</mixed-citation><mixed-citation xml:lang="en">Makris D., Moschandreas J., Damianaki A. et al. Exacerbations and lung function decline in COPD: new insights in current and ex"smokers. Respir. Med. 2007; 101 (6): 1305–1312.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double"blind, placebo"controlled, randomised trial. Lancet. 2001; 357 (9268): 1571–1575.</mixed-citation><mixed-citation xml:lang="en">Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double"blind, placebo"controlled, randomised trial. Lancet. 2001; 357 (9268): 1571–1575.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Jiménez"Ruiz C.A., Masa F., Miravitlles M. et al. Smoking characteristics: diff erences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001; 119 (5): 1365–1370.</mixed-citation><mixed-citation xml:lang="en">Jiménez"Ruiz C.A., Masa F., Miravitlles M. et al. Smoking characteristics: diff erences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001; 119 (5): 1365–1370.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur. Respir. J. 2009; 34 (3): 634–640.</mixed-citation><mixed-citation xml:lang="en">Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network metaanalysis of randomised trials. Eur. Respir. J. 2009; 34 (3): 634–640.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">van der Meer R.M., Wagena E.J., Ostelo R.W. et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2003; (2): CD002999.</mixed-citation><mixed-citation xml:lang="en">van der Meer R.M., Wagena E.J., Ostelo R.W. et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2003; (2): CD002999.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Tønnesen P., Carrozzi L., Fagerström K.O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. 2007; 29 (2): 390–417.</mixed-citation><mixed-citation xml:lang="en">Tønnesen P., Carrozzi L., Fagerström K.O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. 2007; 29 (2): 390–417.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Au D.H., Bryson C.L., Chien J.W. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J. Gen. Intern. Med. 2009; 24 (4): 457–463.</mixed-citation><mixed-citation xml:lang="en">Au D.H., Bryson C.L., Chien J.W. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J. Gen. Intern. Med. 2009; 24 (4): 457–463.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Christenhusz L.C., Prenger R., Pieterse M.E. et al. Costeffectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob. Res. 2012; 14 (6): 657–663.</mixed-citation><mixed-citation xml:lang="en">Christenhusz L.C., Prenger R., Pieterse M.E. et al. Costeffectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob. Res. 2012; 14 (6): 657–663.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Borglykke A., Pisinger C., Jørgensen T., Ibsen H. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). Clin. Respir. J. 2008; 2 (3): 158–165.</mixed-citation><mixed-citation xml:lang="en">Borglykke A., Pisinger C., Jørgensen T., Ibsen H. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD). Clin. Respir. J. 2008; 2 (3): 158–165.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Godtfredsen N.S., Vestbo J., Osler M., Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002; 57 (11): 967–972.</mixed-citation><mixed-citation xml:lang="en">Godtfredsen N.S., Vestbo J., Osler M., Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002; 57 (11): 967–972.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Szabo E., Mao J.T., Lam S. et al. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2013; 143 (5, Suppl.): e40S–e60S.</mixed-citation><mixed-citation xml:lang="en">Szabo E., Mao J.T., Lam S. et al. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2013; 143 (5, Suppl.): e40S–e60S.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Spruit M.A., Singh S.J., Garvey C. et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society / European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188 (8): e13– e64.</mixed-citation><mixed-citation xml:lang="en">Spruit M.A., Singh S.J., Garvey C. et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society / European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013; 188 (8): e13– e64.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Marciniuk D.D., Brooks D., Butcher S. et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can. Respir. J. 2010; 17 (4): 159–168.</mixed-citation><mixed-citation xml:lang="en">Marciniuk D.D., Brooks D., Butcher S. et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can. Respir. J. 2010; 17 (4): 159–168.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence"based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S–42S.</mixed-citation><mixed-citation xml:lang="en">Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence"based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S–42S.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Lacasse Y., Goldstein R., Lasserson T.J., Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (4): CD003793.</mixed-citation><mixed-citation xml:lang="en">Lacasse Y., Goldstein R., Lasserson T.J., Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (4): CD003793.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Lacasse Y., Wong E., Guyatt G.H. et al. Meta"analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996; 348 (9035): 1115–1119.</mixed-citation><mixed-citation xml:lang="en">Lacasse Y., Wong E., Guyatt G.H. et al. Meta"analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996; 348 (9035): 1115–1119.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Nici L., ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient. Proc. Am. Thorac. Soc. 2012; 9 (1): 9–18.</mixed-citation><mixed-citation xml:lang="en">Nici L., ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient. Proc. Am. Thorac. Soc. 2012; 9 (1): 9–18.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Ko F.W., Dai D.L., Ngai J. et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011; 16 (4): 617–624.</mixed-citation><mixed-citation xml:lang="en">Ko F.W., Dai D.L., Ngai J. et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011; 16 (4): 617–624.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Behnke M., Taube C., Kirsten D. et al. Home"based exercise is capable of preserving hospital"based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (12): 1184–1191.</mixed-citation><mixed-citation xml:lang="en">Behnke M., Taube C., Kirsten D. et al. Home"based exercise is capable of preserving hospital"based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (12): 1184–1191.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy N., Bell C., Costello R.W. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir. Med. 2005; 99 (10): 1297–1302.</mixed-citation><mixed-citation xml:lang="en">Murphy N., Bell C., Costello R.W. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir. Med. 2005; 99 (10): 1297–1302.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Ringbaek T., Brondum E., Martinez G. et al. Long"term effects of 1"year maintenance training on physical functioning and health status in patients with COPD: a randomized controlled study. J. Cardiopulm. Rehabil. Prev. 2010; 30 (1): 47–52.</mixed-citation><mixed-citation xml:lang="en">Ringbaek T., Brondum E., Martinez G. et al. Long"term effects of 1"year maintenance training on physical functioning and health status in patients with COPD: a randomized controlled study. J. Cardiopulm. Rehabil. Prev. 2010; 30 (1): 47–52.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Román M., Larraz C., Gómez A. et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. BMC Fam. Pract. 2013; 14: 21.</mixed-citation><mixed-citation xml:lang="en">Román M., Larraz C., Gómez A. et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. BMC Fam. Pract. 2013; 14: 21.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Man W.D., Polkey M.I., Donaldson N. et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. Br. Med. J. 2004; 329 (7476): 1209.</mixed-citation><mixed-citation xml:lang="en">Man W.D., Polkey M.I., Donaldson N. et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. Br. Med. J. 2004; 329 (7476): 1209.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Seymour J.M., Moore L., Jolley C.J. et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010; 65 (5): 423–428.</mixed-citation><mixed-citation xml:lang="en">Seymour J.M., Moore L., Jolley C.J. et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010; 65 (5): 423–428.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Boxall A.M., Barclay L., Sayers A., Caplan G.A. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home"based pulmonary rehabilitation for elderly housebound patients. J. Cardiopulm. Rehabil. 2005; 25 (6): 378–385.</mixed-citation><mixed-citation xml:lang="en">Boxall A.M., Barclay L., Sayers A., Caplan G.A. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home"based pulmonary rehabilitation for elderly housebound patients. J. Cardiopulm. Rehabil. 2005; 25 (6): 378–385.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Eaton T., Young P., Fergusson W. et al. Does early pulmonary rehabilitation reduce acute health"care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology. 2009; 14 (2): 230–238.</mixed-citation><mixed-citation xml:lang="en">Eaton T., Young P., Fergusson W. et al. Does early pulmonary rehabilitation reduce acute health"care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology. 2009; 14 (2): 230–238.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Puhan M.A., Gimeno"Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD005305.</mixed-citation><mixed-citation xml:lang="en">Puhan M.A., Gimeno"Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (10): CD005305.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness? Eff. Clin. Pract. 1998; 1 (1): 2–4.</mixed-citation><mixed-citation xml:lang="en">Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness? Eff. Clin. Pract. 1998; 1 (1): 2–4.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Case Management Society of America. What is a case manager? Case Management Society of America website. http://www.cmsa.org/Home/CMSA/WhatisaCaseManager/ tabid/224/Default.aspx. Accessed March 18, 2014.</mixed-citation><mixed-citation xml:lang="en">Case Management Society of America. What is a case manager? Case Management Society of America website. http://www.cmsa.org/Home/CMSA/WhatisaCaseManager/ tabid/224/Default.aspx. Accessed March 18, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Zwerink M., Brusse"Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD002990.</mixed-citation><mixed-citation xml:lang="en">Zwerink M., Brusse"Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2014; (3): CD002990.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Jarab A.S., Alqudah S.G., Khdour M. et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int. J. Clin. Pharmacol. 2012; 34 (1): 53–62.</mixed-citation><mixed-citation xml:lang="en">Jarab A.S., Alqudah S.G., Khdour M. et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int. J. Clin. Pharmacol. 2012; 34 (1): 53–62.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Farrero E., Escarrabill J., Prats E. et al. Impact of a hospital"based home"care program on the management of COPD patients receiving long"term oxygen therapy. Chest. 2001; 119 (2): 364–369.</mixed-citation><mixed-citation xml:lang="en">Farrero E., Escarrabill J., Prats E. et al. Impact of a hospital"based home"care program on the management of COPD patients receiving long"term oxygen therapy. Chest. 2001; 119 (2): 364–369.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Lainscak M., Kadivec S., Kosnik M. et al. Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. J. Am. Med. Dir. Assoc. 2013; 14 (6): 450.e1– 450.e6.</mixed-citation><mixed-citation xml:lang="en">Lainscak M., Kadivec S., Kosnik M. et al. Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. J. Am. Med. Dir. Assoc. 2013; 14 (6): 450.e1– 450.e6.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Smith B.J., Appleton S.L., Bennett P.W. et al. The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med. 1999; 29 (5): 718–725.</mixed-citation><mixed-citation xml:lang="en">Smith B.J., Appleton S.L., Bennett P.W. et al. The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med. 1999; 29 (5): 718–725.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Soler J.J., Martínez"García M.A., Román P. et al. Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations. Arch. Bronconeumol. 2006; 42 (10): 501–508 (in Spanish).</mixed-citation><mixed-citation xml:lang="en">Soler J.J., Martínez"García M.A., Román P. et al. Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations. Arch. Bronconeumol. 2006; 42 (10): 501–508 (in Spanish).</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Gallefoss F. The effects of patient education in COPD in a 1"year follow"up randomised, controlled trial. Patient Educ. Couns. 2004; 52 (3): 259–266.</mixed-citation><mixed-citation xml:lang="en">Gallefoss F. The effects of patient education in COPD in a 1"year follow"up randomised, controlled trial. Patient Educ. Couns. 2004; 52 (3): 259–266.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">McGeoch G.R., Willsman K.J., Dowson C.A. et al. Selfmanagement plans in the primary care of patients with chronic obstructive pulmonary disease. Respirology. 2006;11 (5): 611–618.</mixed-citation><mixed-citation xml:lang="en">McGeoch G.R., Willsman K.J., Dowson C.A. et al. Selfmanagement plans in the primary care of patients with chronic obstructive pulmonary disease. Respirology. 2006;11 (5): 611–618.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Wakabayashi R., Motegi T., Yamada K. et al. Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire. Geriatr. Gerontol. Int. 2011; 11 (4):422–430.</mixed-citation><mixed-citation xml:lang="en">Wakabayashi R., Motegi T., Yamada K. et al. Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire. Geriatr. Gerontol. Int. 2011; 11 (4):422–430.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Wood"Baker R., McGlone S., Venn A., Walters E.H. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations. Respirology. 2006; 11 (5): 619–626.</mixed-citation><mixed-citation xml:lang="en">Wood"Baker R., McGlone S., Venn A., Walters E.H. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations. Respirology. 2006; 11 (5): 619–626.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Bourbeau J., Julien M., Maltais F. et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a diseasespecific self"management intervention. Arch. Intern. Med. 2003; 163 (5): 585–591.</mixed-citation><mixed-citation xml:lang="en">Bourbeau J., Julien M., Maltais F. et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a diseasespecific self"management intervention. Arch. Intern. Med. 2003; 163 (5): 585–591.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Casas A., Troosters T., Garcia"Aymerich J. et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J. 2006; 28 (1): 123–130.</mixed-citation><mixed-citation xml:lang="en">Casas A., Troosters T., Garcia"Aymerich J. et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J. 2006; 28 (1): 123–130.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Fan V.S., Gaziano J.M., Lew R. et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann. Intern. Med. 2012; 156 (10): 673–683.</mixed-citation><mixed-citation xml:lang="en">Fan V.S., Gaziano J.M., Lew R. et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann. Intern. Med. 2012; 156 (10): 673–683.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Khdour M.R., Kidney J.C., Smyth B.M., McElnay J.C. Clinical pharmacy"led disease and medicine management programme for patients with COPD. Br. J. Clin. Pharmacol. 2009; 68 (4): 588–598.</mixed-citation><mixed-citation xml:lang="en">Khdour M.R., Kidney J.C., Smyth B.M., McElnay J.C. Clinical pharmacy"led disease and medicine management programme for patients with COPD. Br. J. Clin. Pharmacol. 2009; 68 (4): 588–598.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Rea H., McAuley S., Stewart A. et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern. Med. J. 2004; 34 (11): 608–614.</mixed-citation><mixed-citation xml:lang="en">Rea H., McAuley S., Stewart A. et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern. Med. J. 2004; 34 (11): 608–614.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Rice K.L., Dewan N., Bloomfield H.E. et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2010; 182 (7): 890–896.</mixed-citation><mixed-citation xml:lang="en">Rice K.L., Dewan N., Bloomfield H.E. et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2010; 182 (7): 890–896.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Trappenburg J.C., Monninkhof E.M., Bourbeau J. et al. Effect of an action plan with ongoing support by a case manager on exacerbation"related outcome in patients with COPD: a multicenter randomised controlled trial. Thorax. 2011; 66 (11): 977–984.</mixed-citation><mixed-citation xml:lang="en">Trappenburg J.C., Monninkhof E.M., Bourbeau J. et al. Effect of an action plan with ongoing support by a case manager on exacerbation"related outcome in patients with COPD: a multicenter randomised controlled trial. Thorax. 2011; 66 (11): 977–984.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Walters J., Cameron"Tucker H., Wills K. et al. Effects of telephone health mentoring in community"recruited chronic obstructive pulmonary disease on self"management capacity, quality of life and psychological morbidity: a randomised controlled trial. Br. Med. J. Open. 2013; 3 (9): e003097.</mixed-citation><mixed-citation xml:lang="en">Walters J., Cameron"Tucker H., Wills K. et al. Effects of telephone health mentoring in community"recruited chronic obstructive pulmonary disease on self"management capacity, quality of life and psychological morbidity: a randomised controlled trial. Br. Med. J. Open. 2013; 3 (9): e003097.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Bischoff E.W., Akkermans R., Bourbeau J. et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. Br. Med. J. 2012; 345: e7642.</mixed-citation><mixed-citation xml:lang="en">Bischoff E.W., Akkermans R., Bourbeau J. et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. Br. Med. J. 2012; 345: e7642.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Coultas D., Frederick J., Barnett B. et al. A randomized trial of two types of nurse"assisted home care for patients with COPD. Chest. 2005; 128 (4): 2017–2024.</mixed-citation><mixed-citation xml:lang="en">Coultas D., Frederick J., Barnett B. et al. A randomized trial of two types of nurse"assisted home care for patients with COPD. Chest. 2005; 128 (4): 2017–2024.</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Gadoury M.A., Schwartzman K., Rouleau M. et al; Chronic Obstructive Pulmonary Disease axis of the Respiratory Health Network, Fonds de la recherche en Santé du Québec (FRSQ). Self"management reduces both short" and long"term hospitalisation in COPD. Eur. Respir. J. 2005; 26 (5): 853–857.</mixed-citation><mixed-citation xml:lang="en">Gadoury M.A., Schwartzman K., Rouleau M. et al; Chronic Obstructive Pulmonary Disease axis of the Respiratory Health Network, Fonds de la recherche en Santé du Québec (FRSQ). Self"management reduces both short" and long"term hospitalisation in COPD. Eur. Respir. J. 2005; 26 (5): 853–857.</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Hermiz O., Comino E., Marks G. et al. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. Br. Med. J. 2002; 325 (7370): 938.</mixed-citation><mixed-citation xml:lang="en">Hermiz O., Comino E., Marks G. et al. Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease. Br. Med. J. 2002; 325 (7370): 938.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Telemedicine: opportunities and developments in member states. Report on the second global survey on eHealth. World Health Organization website. http://www.who.int/ goe/publications/goe_telemedicine_2010.pdf. Accessed March 13, 2014.</mixed-citation><mixed-citation xml:lang="en">Telemedicine: opportunities and developments in member states. Report on the second global survey on eHealth. World Health Organization website. http://www.who.int/ goe/publications/goe_telemedicine_2010.pdf. Accessed March 13, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">What is telemedicine? American Telemedicine Association website. http://www.americantelemed.org/about#telemedicine/what#is#telemedi cine. Accessed March 13, 2014.</mixed-citation><mixed-citation xml:lang="en">What is telemedicine? American Telemedicine Association website. http://www.americantelemed.org/about#telemedicine/what#is#telemedi cine. Accessed March 13, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">de Toledo P., Jiménez S., del Pozo F. et al. Telemedicine experience for chronic care in COPD. IEEE Trans. Inf. Technol. Biomed. 2006; 10 (3): 567–573.</mixed-citation><mixed-citation xml:lang="en">de Toledo P., Jiménez S., del Pozo F. et al. Telemedicine experience for chronic care in COPD. IEEE Trans. Inf. Technol. Biomed. 2006; 10 (3): 567–573.</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Vitacca M., Bianchi L., Guerra A. et al. Tele"assistance in chronic respiratory failure patients: a randomised clinical trial. Eur. Respir. J. 2009; 33 (2): 411–418.</mixed-citation><mixed-citation xml:lang="en">Vitacca M., Bianchi L., Guerra A. et al. Tele"assistance in chronic respiratory failure patients: a randomised clinical trial. Eur. Respir. J. 2009; 33 (2): 411–418.</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Wong K.W., Wong F.K., Chan M.F. Effects of nurse"initiated telephone follow"up on self"efficacy among patients with chronic obstructive pulmonary disease. J. Adv. Nurs. 2005; 49 (2): 210–222.</mixed-citation><mixed-citation xml:lang="en">Wong K.W., Wong F.K., Chan M.F. Effects of nurse"initiated telephone follow"up on self"efficacy among patients with chronic obstructive pulmonary disease. J. Adv. Nurs. 2005; 49 (2): 210–222.</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">McLean S., Nurmatov U., Liu J.L. et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (7): CD007718.</mixed-citation><mixed-citation xml:lang="en">McLean S., Nurmatov U., Liu J.L. et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (7): CD007718.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Antoniades N.C., Rochford P.D., Pretto J.J. et al. Pilot study of remote telemonitoring in COPD. Telemed. J. E. Health. 2012; 18 (8): 634–640.</mixed-citation><mixed-citation xml:lang="en">Antoniades N.C., Rochford P.D., Pretto J.J. et al. Pilot study of remote telemonitoring in COPD. Telemed. J. E. Health. 2012; 18 (8): 634–640.</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Chau J.P., Lee D.T., Yu D.S. et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int. J. Med. Inform. 2012; 81 (10): 674–682.</mixed-citation><mixed-citation xml:lang="en">Chau J.P., Lee D.T., Yu D.S. et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int. J. Med. Inform. 2012; 81 (10): 674–682.</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Dinesen B., Haesum L.K., Soerensen N. et al. Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients. J. Telemed. Telecare. 2012; 18 (4): 221–225.</mixed-citation><mixed-citation xml:lang="en">Dinesen B., Haesum L.K., Soerensen N. et al. Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients. J. Telemed. Telecare. 2012; 18 (4): 221–225.</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Gellis Z.D., Kenaley B., McGinty J. et al. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. Gerontologist. 2012; 52 (4): 541–552.</mixed-citation><mixed-citation xml:lang="en">Gellis Z.D., Kenaley B., McGinty J. et al. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. Gerontologist. 2012; 52 (4): 541–552.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Haesum L.K., Soerensen N., Dinesen B. et al. Cost"utility analysis of a telerehabilitation program: a case study of COPD patients. Telemed. J. E. Health. 2012; 18 (9): 688–692.</mixed-citation><mixed-citation xml:lang="en">Haesum L.K., Soerensen N., Dinesen B. et al. Cost"utility analysis of a telerehabilitation program: a case study of COPD patients. Telemed. J. E. Health. 2012; 18 (9): 688–692.</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Halpin D.M., Laing"Morton T., Spedding S. et al. A randomized controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim. Care Respir. J. 2011; 20 (3): 324–331.</mixed-citation><mixed-citation xml:lang="en">Halpin D.M., Laing"Morton T., Spedding S. et al. A randomized controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim. Care Respir. J. 2011; 20 (3): 324–331.</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Henderson C., Knapp M., Fernández J.L. et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. Br. Med. J. 2013; 346: f1035.</mixed-citation><mixed-citation xml:lang="en">Henderson C., Knapp M., Fernández J.L. et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. Br. Med. J. 2013; 346: f1035.</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Holland A. Telehealth reduces hospital admission rates in patients with COPD. J. Physiother. 2013; 59 (2): 129.</mixed-citation><mixed-citation xml:lang="en">Holland A. Telehealth reduces hospital admission rates in patients with COPD. J. Physiother. 2013; 59 (2): 129.</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Jódar"Sánchez F., Ortega F., Parra C. et al. Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long"term oxygen therapy. J. Telemed. Telecare. 2013; 19 (1): 11–17.</mixed-citation><mixed-citation xml:lang="en">Jódar"Sánchez F., Ortega F., Parra C. et al. Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long"term oxygen therapy. J. Telemed. Telecare. 2013; 19 (1): 11–17.</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Koff P.B., Jones R.H., Cashman J.M. et al. Proactive integrated care improves quality of life in patients with COPD. Eur. Respir. J. 2009; 33 (5): 1031–1038.</mixed-citation><mixed-citation xml:lang="en">Koff P.B., Jones R.H., Cashman J.M. et al. Proactive integrated care improves quality of life in patients with COPD. Eur. Respir. J. 2009; 33 (5): 1031–1038.</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Lewis K.E., Annandale J.A., Warm D.L. et al. Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD. 2010; 7 (1): 44–50.</mixed-citation><mixed-citation xml:lang="en">Lewis K.E., Annandale J.A., Warm D.L. et al. Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD. 2010; 7 (1): 44–50.</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Paré G., Poba"Nzaou P., Sicotte C. et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized controlled trial. Eur. Res. Telemed. 2013; 2 (2): 35– 47.</mixed-citation><mixed-citation xml:lang="en">Paré G., Poba"Nzaou P., Sicotte C. et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized controlled trial. Eur. Res. Telemed. 2013; 2 (2): 35– 47.</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Pedone C., Chiurco D., Scarlata S., Incalzi R.A. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv. Res. 2013; 13: 82.</mixed-citation><mixed-citation xml:lang="en">Pedone C., Chiurco D., Scarlata S., Incalzi R.A. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv. Res. 2013; 13: 82.</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Pinnock H., Hanley J., Lewis S. et al. The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim. Care Respir. J. 2009; 18 (3): 233–235.</mixed-citation><mixed-citation xml:lang="en">Pinnock H., Hanley J., Lewis S. et al. The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim. Care Respir. J. 2009; 18 (3): 233–235.</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Shany T., Hession M., Pryce D. et al. Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. Stud. Health Technol. Inform. 2010; 161: 139–148.</mixed-citation><mixed-citation xml:lang="en">Shany T., Hession M., Pryce D. et al. Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. Stud. Health Technol. Inform. 2010; 161: 139–148.</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Sorknaes A.D., Madsen H., Hallas J. et al. Nurse teleconsultations with discharged COPD patients reduce early readmissions"an interventional study. Clin. Respir. J. 2011; 5 (1): 26–34.</mixed-citation><mixed-citation xml:lang="en">Sorknaes A.D., Madsen H., Hallas J. et al. Nurse teleconsultations with discharged COPD patients reduce early readmissions"an interventional study. Clin. Respir. J. 2011; 5 (1): 26–34.</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Steventon A., Bardsley M., Billings J. et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. Br. Med. J. 2012; 344: e3874.</mixed-citation><mixed-citation xml:lang="en">Steventon A., Bardsley M., Billings J. et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial. Br. Med. J. 2012; 344: e3874.</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Venter A., Burns R., Hefford M., Ehrenberg N. Results of a telehealthenabled chronic care management service to support people with long"term conditions at home. J. Telemed. Telecare. 2012; 18 (3): 172–175.</mixed-citation><mixed-citation xml:lang="en">Venter A., Burns R., Hefford M., Ehrenberg N. Results of a telehealthenabled chronic care management service to support people with long"term conditions at home. J. Telemed. Telecare. 2012; 18 (3): 172–175.</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Wootton R. Twenty years of telemedicine in chronic disease management – an evidence synthesis. J. Telemed. Telecare. 2012; 18 (4): 211–220.</mixed-citation><mixed-citation xml:lang="en">Wootton R. Twenty years of telemedicine in chronic disease management – an evidence synthesis. J. Telemed. Telecare. 2012; 18 (4): 211–220.</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Kew K.M., Mavergames C., Walters J.A. Long"acting beta2"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (10): CD010177.</mixed-citation><mixed-citation xml:lang="en">Kew K.M., Mavergames C., Walters J.A. Long"acting beta2"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (10): CD010177.</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Vestbo J., Hurd S.S., Agustí A.G. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187 (4): 347–365.</mixed-citation><mixed-citation xml:lang="en">Vestbo J., Hurd S.S., Agustí A.G. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2013; 187 (4): 347–365.</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A meta"analysis. Thorax. 2006; 61 (10): 854–862.</mixed-citation><mixed-citation xml:lang="en">Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotropium for stable chronic obstructive pulmonary disease: A meta"analysis. Thorax. 2006; 61 (10): 854–862.</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta"analysis of randomised controlled trials. Br. Med. J. 2011; 342: d3215.</mixed-citation><mixed-citation xml:lang="en">Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta"analysis of randomised controlled trials. Br. Med. J. 2011; 342: d3215.</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501.</mixed-citation><mixed-citation xml:lang="en">Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501.</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD009285.</mixed-citation><mixed-citation xml:lang="en">Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD009285.</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">O′Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.</mixed-citation><mixed-citation xml:lang="en">O′Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">O′Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840.</mixed-citation><mixed-citation xml:lang="en">O′Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840.</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124 (5): 1743–1748.</mixed-citation><mixed-citation xml:lang="en">Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124 (5): 1743–1748.</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">O′Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24 (1): 86–94.</mixed-citation><mixed-citation xml:lang="en">O′Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24 (1): 86–94.</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.</mixed-citation><mixed-citation xml:lang="en">Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8): 775–789.</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Chong J., Karner C., Poole P. Tiotropium versus long"acting beta"agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD009157.</mixed-citation><mixed-citation xml:lang="en">Chong J., Karner C., Poole P. Tiotropium versus long"acting beta"agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD009157.</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103.</mixed-citation><mixed-citation xml:lang="en">Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103.</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long"acting beta"2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (3): CD006101.</mixed-citation><mixed-citation xml:lang="en">Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long"acting beta"2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; (3): CD006101.</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Brown D. et al. A randomized, double blind, parallel, multi"centre comparison of inhalation solution with albuterol inhalation solution following single"dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0865; 1991.</mixed-citation><mixed-citation xml:lang="en">Brown D. et al. A randomized, double blind, parallel, multi"centre comparison of inhalation solution with albuterol inhalation solution following single"dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0865; 1991.</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Brown D. et al. A randomized, double blind, parallel, multicenter comparison of Atrovent (ipratropium bromide) inhalation solution with metaproterenol inhalation solution following single"dose and chronic administration (85 days) in patient with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0866; 1991.</mixed-citation><mixed-citation xml:lang="en">Brown D. et al. A randomized, double blind, parallel, multicenter comparison of Atrovent (ipratropium bromide) inhalation solution with metaproterenol inhalation solution following single"dose and chronic administration (85 days) in patient with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0866; 1991.</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman M. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S30–S39.</mixed-citation><mixed-citation xml:lang="en">Friedman M. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S30–S39.</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest. 1996; 110 (1): 62–70.</mixed-citation><mixed-citation xml:lang="en">Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest. 1996; 110 (1): 62–70.</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Tashkin D.P., Ashutosh K., Bleecker E.R. et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90"day multi"center study. Am. J. Med. 1986; 81 (5A): 81–90.</mixed-citation><mixed-citation xml:lang="en">Tashkin D.P., Ashutosh K., Bleecker E.R. et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90"day multi"center study. Am. J. Med. 1986; 81 (5A): 81–90.</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Tashkin D.P., Bleecker E., Braun S. et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am. J. Med. 1996; 100 (Suppl. 1): S62–S69.</mixed-citation><mixed-citation xml:lang="en">Tashkin D.P., Bleecker E., Braun S. et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am. J. Med. 1996; 100 (Suppl. 1): S62–S69.</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85"day multicenter trial. Chest. 1994; 105 (5): 1411–1419.</mixed-citation><mixed-citation xml:lang="en">COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85"day multicenter trial. Chest. 1994; 105 (5): 1411–1419.</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997; 112 (6): 1514–1521.</mixed-citation><mixed-citation xml:lang="en">COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997; 112 (6): 1514–1521.</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Colice G.L. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S11–S18.</mixed-citation><mixed-citation xml:lang="en">Colice G.L. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S11–S18.</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch. Intern. Med. 1999; 159 (2): 156–160.</mixed-citation><mixed-citation xml:lang="en">Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch. Intern. Med. 1999; 159 (2): 156–160.</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander K.M. et al. A randomized, double blind, parallel, multicenter comparison of Combivent (ipratropium bromide and albuterol sulfate) inhalation solution with its components following single"dose and chronic administration (85 days) in patients with chronic pulmonary disease. Boehringer Ingelheim unpublished report: USA U92"0801; 1992.</mixed-citation><mixed-citation xml:lang="en">Alexander K.M. et al. A randomized, double blind, parallel, multicenter comparison of Combivent (ipratropium bromide and albuterol sulfate) inhalation solution with its components following single"dose and chronic administration (85 days) in patients with chronic pulmonary disease. Boehringer Ingelheim unpublished report: USA U92"0801; 1992.</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Gross N., Tashkin D., Miller R et al. Inhalation by nebulization of albuterol"ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration. 1998; 65 (5): 354–362.</mixed-citation><mixed-citation xml:lang="en">Gross N., Tashkin D., Miller R et al. Inhalation by nebulization of albuterol"ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration. 1998; 65 (5): 354–362.</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Levin D.C., Little K.S., Laughlin K.R. et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta"2 agonists in patients with chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S40–S48.</mixed-citation><mixed-citation xml:lang="en">Levin D.C., Little K.S., Laughlin K.R. et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta"2 agonists in patients with chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (Suppl. 1): S40–S48.</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000; 55(4): 289–294.</mixed-citation><mixed-citation xml:lang="en">van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000; 55(4): 289–294.</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115 (4): 957–965.</mixed-citation><mixed-citation xml:lang="en">Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115 (4): 957–965.</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Cramer J.A., Bradley"Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14 (1): 25–29.</mixed-citation><mixed-citation xml:lang="en">Cramer J.A., Bradley"Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14 (1): 25–29.</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">O’Donnell D.E., Revill S.M., Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (5): 770–777.</mixed-citation><mixed-citation xml:lang="en">O’Donnell D.E., Revill S.M., Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (5): 770–777.</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272 (19): 1497–1505.</mixed-citation><mixed-citation xml:lang="en">Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272 (19): 1497–1505.</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Cheyne L., Irvin"Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (9): CD009552.</mixed-citation><mixed-citation xml:lang="en">Cheyne L., Irvin"Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (9): CD009552.</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Loke Y.K., Singh S., Furberg C.D. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 480–481.</mixed-citation><mixed-citation xml:lang="en">Loke Y.K., Singh S., Furberg C.D. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 480–481.</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Verhamme K.M., van Blijderveen N., Sturkenboom M.C. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 481–482.</mixed-citation><mixed-citation xml:lang="en">Verhamme K.M., van Blijderveen N., Sturkenboom M.C. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 481–482.</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Jenkins C.R. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 482–483.</mixed-citation><mixed-citation xml:lang="en">Jenkins C.R. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 482–483.</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Sethi S., Mahler D.A., Marcus P. et al. Inflammation in COPD: implications for management. Am. J. Med. 2012;125 (12): 1162–1170.</mixed-citation><mixed-citation xml:lang="en">Sethi S., Mahler D.A., Marcus P. et al. Inflammation in COPD: implications for management. Am. J. Med. 2012;125 (12): 1162–1170.</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Izquierdo Alonso J.L., Rodíguez Glez"Moro J.M. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch. Bronconeumol. 2012; 48 (6): 207–212.</mixed-citation><mixed-citation xml:lang="en">Izquierdo Alonso J.L., Rodíguez Glez"Moro J.M. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. Arch. Bronconeumol. 2012; 48 (6): 207–212.</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">de Miguel"Díez J., Carrasco"Garrido P., Rejas"Gutierrez J. et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung. 2011; 189 (3): 199–206.</mixed-citation><mixed-citation xml:lang="en">de Miguel"Díez J., Carrasco"Garrido P., Rejas"Gutierrez J. et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung. 2011; 189 (3): 199–206.</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010; 80 (2): 89–95.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J. Inhaled corticosteroids in COPD: a controversy. Respiration. 2010; 80 (2): 89–95.</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Price D., Yawn B., Brusselle G., Rossi A. Risk"to"benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100.</mixed-citation><mixed-citation xml:lang="en">Price D., Yawn B., Brusselle G., Rossi A. Risk"to"benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100.</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Zervas E., Samitas K., Gaga M. et al. Inhaled corticosteroids in COPD: pros and cons. Curr. Drug Targets. 2013; 14 (2): 192–224.</mixed-citation><mixed-citation xml:lang="en">Zervas E., Samitas K., Gaga M. et al. Inhaled corticosteroids in COPD: pros and cons. Curr. Drug Targets. 2013; 14 (2): 192–224.</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Ann. Rev. Physiol. 2009; 71: 451–464.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Ann. Rev. Physiol. 2009; 71: 451–464.</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011; 163 (1): 29–43.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011; 163 (1): 29–43.</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Mercado N., Thimmulappa R., Thomas C.M.R. et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 2011; 406 (2): 292–298.</mixed-citation><mixed-citation xml:lang="en">Mercado N., Thimmulappa R., Thomas C.M.R. et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 2011; 406 (2): 292–298.</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">Jen R., Rennard S.I., Sin D.D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta"analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2012; 7: 587–595.</mixed-citation><mixed-citation xml:lang="en">Jen R., Rennard S.I., Sin D.D. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta"analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2012; 7: 587–595.</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009; 6 (5): 320–329.</mixed-citation><mixed-citation xml:lang="en">Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009; 6 (5): 320–329.</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Boscia J.A., Pudi K.K., Zvarich M.T. et al. Effect of oncedaily fluticasone furoate/vilanterol on 24"hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three"way, incomplete block, crossover study. Clin. Ther. 2012; 34 (8): 1655–1666.</mixed-citation><mixed-citation xml:lang="en">Boscia J.A., Pudi K.K., Zvarich M.T. et al. Effect of oncedaily fluticasone furoate/vilanterol on 24"hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three"way, incomplete block, crossover study. Clin. Ther. 2012; 34 (8): 1655–1666.</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320 (7245): 1297–1303.</mixed-citation><mixed-citation xml:lang="en">Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320 (7245): 1297–1303.</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912–919.</mixed-citation><mixed-citation xml:lang="en">Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912–919.</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Dransfield M.T., Bourbeau J., Jones P.W. et al. Once"daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double"blind, parallel"group, randomised controlled trials. Lancet Respir. Med. 2013; 1 (3): 210–223.</mixed-citation><mixed-citation xml:lang="en">Dransfield M.T., Bourbeau J., Jones P.W. et al. Once"daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double"blind, parallel"group, randomised controlled trials. Lancet Respir. Med. 2013; 1 (3): 210–223.</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Ferguson G.T., Anzueto A., Fei R. et al. Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir. Med. 2008; 102 (8): 1099–1108.</mixed-citation><mixed-citation xml:lang="en">Ferguson G.T., Anzueto A., Fei R. et al. Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir. Med. 2008; 102 (8): 1099–1108.</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 mg) / salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 124(3): 834–843.</mixed-citation><mixed-citation xml:lang="en">Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 mg) / salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003; 124(3): 834–843.</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Kerwin E.M., Scott"Wilson C., Sanford L. et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir. Med. 2013;107 (4): 560–569.</mixed-citation><mixed-citation xml:lang="en">Kerwin E.M., Scott"Wilson C., Sanford L. et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir. Med. 2013;107 (4): 560–569.</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Lapperre T.S., Snoeck"Stroband J.B., Gosman M.M.E. et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2009; 151 (8): 517–527.</mixed-citation><mixed-citation xml:lang="en">Lapperre T.S., Snoeck"Stroband J.B., Gosman M.M.E. et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2009; 151 (8): 517–527.</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.</mixed-citation><mixed-citation xml:lang="en">Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166 (8): 1084–1091.</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez F.J., Boscia J., Feldman G. et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir. Med. 2013; 107 (4): 550–559.</mixed-citation><mixed-citation xml:lang="en">Martinez F.J., Boscia J., Feldman G. et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir. Med. 2013; 107 (4): 550–559.</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Sharafkhaneh A., Southard J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double"blind, randomized study. Respir. Med. 2012; 106 (2): 257–268.</mixed-citation><mixed-citation xml:lang="en">Sharafkhaneh A., Southard J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double"blind, randomized study. Respir. Med. 2012; 106 (2): 257–268.</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 74–81.</mixed-citation><mixed-citation xml:lang="en">Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 74–81.</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010; 137 (2): 318–325.</mixed-citation><mixed-citation xml:lang="en">Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010; 137 (2): 318–325.</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Glaab T., Taube C. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2011; 24 (1): 15–22.</mixed-citation><mixed-citation xml:lang="en">Glaab T., Taube C. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2011; 24 (1): 15–22.</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Spencer S., Karner C., Cates C.J., Evans D.J. Inhaled corticosteroids versus long"acting beta"2"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 12: CD007033.</mixed-citation><mixed-citation xml:lang="en">Spencer S., Karner C., Cates C.J., Evans D.J. Inhaled corticosteroids versus long"acting beta"2"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 12: CD007033.</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">van Grunsven P.M., van Schayck C.P., Derenne J.P. et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta"analysis. Thorax. 1999; 54 (1): 7–14.</mixed-citation><mixed-citation xml:lang="en">van Grunsven P.M., van Schayck C.P., Derenne J.P. et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta"analysis. Thorax. 1999; 54 (1): 7–14.</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 7: CD002991.</mixed-citation><mixed-citation xml:lang="en">Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 7: CD002991.</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice"daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40 (4): 830–836.</mixed-citation><mixed-citation xml:lang="en">Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice"daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40 (4): 830–836.</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once"daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326.</mixed-citation><mixed-citation xml:lang="en">Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once"daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326.</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Di Marco F., Santus P. et al. The pharmacodynamics effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 2004; 17 (1): 35–39.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Di Marco F., Santus P. et al. The pharmacodynamics effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 2004; 17 (1): 35–39.</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Gross N.J., Nelson H.S., Lapidus R.J. et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir. Med. 2008; 102 (2): 189–197.</mixed-citation><mixed-citation xml:lang="en">Gross N.J., Nelson H.S., Lapidus R.J. et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir. Med. 2008; 102 (2): 189–197.</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Tashkin D.P., Cooper C.B. The role of long"acting bronchodilators in the management of stable COPD. Chest. 2004; 125 (1): 249–259.</mixed-citation><mixed-citation xml:lang="en">Tashkin D.P., Cooper C.B. The role of long"acting bronchodilators in the management of stable COPD. Chest. 2004; 125 (1): 249–259.</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545–555.</mixed-citation><mixed-citation xml:lang="en">Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545–555.</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006; 61 (1): 91.</mixed-citation><mixed-citation xml:lang="en">Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2006; 61 (1): 91.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J., Pocock S.J., Magnussen H. et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther. 2010; 23 (3): 165–171.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J., Pocock S.J., Magnussen H. et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther. 2010; 23 (3): 165–171.</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Beier J., Chanez P., Martinot J.B. et al. Safety, tolerability and efficacy of indacaterol, a novel once"daily beta"2"agonist, in patients with COPD: a 28"day randomised, placebo controlled clinical trial. Pulm. Pharmacol. Ther. 2007; 20 (6): 740–749.</mixed-citation><mixed-citation xml:lang="en">Beier J., Chanez P., Martinot J.B. et al. Safety, tolerability and efficacy of indacaterol, a novel once"daily beta"2"agonist, in patients with COPD: a 28"day randomised, placebo controlled clinical trial. Pulm. Pharmacol. Ther. 2007; 20 (6): 740–749.</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Jones P.W., Mahler D.A., Gale R. et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir. Med. 2011; 105 (6): 892–899.</mixed-citation><mixed-citation xml:lang="en">Jones P.W., Mahler D.A., Gale R. et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir. Med. 2011; 105 (6): 892–899.</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Santus P., Di Marco F. et al. Bronchodilator effect of an inhaled combination therapy with salmeterol 1 fluticasone and formoterol 1 budesonide in patients with COPD. Respir. Med. 2003; 97 (5): 453–457.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Santus P., Di Marco F. et al. Bronchodilator effect of an inhaled combination therapy with salmeterol 1 fluticasone and formoterol 1 budesonide in patients with COPD. Respir. Med. 2003; 97 (5): 453–457.</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21 (1): 68–73.</mixed-citation><mixed-citation xml:lang="en">Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21 (1): 68–73.</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Vestbo J., Soriano J.B., Anderson J.A. et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir. Med. 2004; 98 (11): 1045–1050.</mixed-citation><mixed-citation xml:lang="en">Vestbo J., Soriano J.B., Anderson J.A. et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir. Med. 2004; 98 (11): 1045–1050.</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1 (2): 121–124.</mixed-citation><mixed-citation xml:lang="en">Calverley P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2004; 1 (2): 121–124.</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigo G.J., Plaza V., Castro"Rodríguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm. Pharmacol. Ther. 2012; 25 (1): 40–47.</mixed-citation><mixed-citation xml:lang="en">Rodrigo G.J., Plaza V., Castro"Rodríguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm. Pharmacol. Ther. 2012; 25 (1): 40–47.</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long"acting beta(2)"agonist in one inhaler versus long"acting beta(2)"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 9: CD006829.</mixed-citation><mixed-citation xml:lang="en">Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long"acting beta(2)"agonist in one inhaler versus long"acting beta(2)"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 9: CD006829.</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel"group study. Lancet Respir. Med. 2013; 1 (3): 199–209.</mixed-citation><mixed-citation xml:lang="en">Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel"group study. Lancet Respir. Med. 2013; 1 (3): 199–209.</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">He Z.Y., Ou L.M., Zhang J.Q. et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010; 80 (6): 445–452.</mixed-citation><mixed-citation xml:lang="en">He Z.Y., Ou L.M., Zhang J.Q. et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010; 80 (6): 445–452.</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Seemungal T.A., Wilkinson T.M., Hurst J.R. et al. Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 178 (11): 1139–1147.</mixed-citation><mixed-citation xml:lang="en">Seemungal T.A., Wilkinson T.M., Hurst J.R. et al. Longterm erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 178 (11): 1139–1147.</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Aaron S.D., Vandemheen K.L., Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 2003; 348 (26): 2618–2625.</mixed-citation><mixed-citation xml:lang="en">Aaron S.D., Vandemheen K.L., Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 2003; 348 (26): 2618–2625.</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999; 354 (9177): 456–460.</mixed-citation><mixed-citation xml:lang="en">Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999; 354 (9177): 456–460.</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340 (25): 1941–1947.</mixed-citation><mixed-citation xml:lang="en">Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340 (25): 1941–1947.</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson W.H., Nielson C.P., Carvalho P. et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. 1996; 154 (2): 407–412.</mixed-citation><mixed-citation xml:lang="en">Thompson W.H., Nielson C.P., Carvalho P. et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. 1996; 154 (2): 407–412.</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Aggarwal P., Wig N., Bhoi S. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2011; 15 (5): 687–692.</mixed-citation><mixed-citation xml:lang="en">Aggarwal P., Wig N., Bhoi S. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. Int. J. Tuberc. Lung Dis. 2011; 15 (5): 687–692.</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Ställberg B., Selroos O., Vogelmeier C. et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double"blind, randomised, non"inferiority, parallel"group, multicentre study. Respir. Res. 2009; 10: 11.</mixed-citation><mixed-citation xml:lang="en">Ställberg B., Selroos O., Vogelmeier C. et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double"blind, randomised, non"inferiority, parallel"group, multicentre study. Respir. Res. 2009; 10: 11.</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am. J. Respir. Crit. Care Med. 2000; 162 (1): 174–178.</mixed-citation><mixed-citation xml:lang="en">Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am. J. Respir. Crit. Care Med. 2000; 162 (1): 174–178.</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374 (9691): 685–694.</mixed-citation><mixed-citation xml:lang="en">Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374 (9691): 685–694.</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Fabbri L.M., Calverley P.M., Izquierdo"Alonso J.L. et al. Roflumilast in moderate"to"severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374 (9691): 695–703.</mixed-citation><mixed-citation xml:lang="en">Fabbri L.M., Calverley P.M., Izquierdo"Alonso J.L. et al. Roflumilast in moderate"to"severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374 (9691): 695–703.</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S.D., Hui D.S., Mahayiddin A.A. et al. Roflumilast in Asian patients with COPD: a randomized placebo"controlled trial. Respirology. 2011; 16 (8): 1249–1257.</mixed-citation><mixed-citation xml:lang="en">Lee S.D., Hui D.S., Mahayiddin A.A. et al. Roflumilast in Asian patients with COPD: a randomized placebo"controlled trial. Respirology. 2011; 16 (8): 1249–1257.</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Rabe K.F., Magnussen H., Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J. 1995; 8 (4): 637–642.</mixed-citation><mixed-citation xml:lang="en">Rabe K.F., Magnussen H., Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J. 1995; 8 (4): 637–642.</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow"release theophylline in the treatment of COPD. Chest. 2002; 121 (4): 1058–1069.</mixed-citation><mixed-citation xml:lang="en">Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow"release theophylline in the treatment of COPD. Chest. 2002; 121 (4): 1058–1069.</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou Y., Wang X., Zeng X. et al. Positive benefits of theophylline in a randomized, double"blind, parallel"group, placebo"controlled study of low"dose, slow"release theophylline in the treatment of COPD for 1 year. Respirology. 2006; 11 (5): 603–610.</mixed-citation><mixed-citation xml:lang="en">Zhou Y., Wang X., Zeng X. et al. Positive benefits of theophylline in a randomized, double"blind, parallel"group, placebo"controlled study of low"dose, slow"release theophylline in the treatment of COPD for 1 year. Respirology. 2006; 11 (5): 603–610.</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Sheffner A.L., Medler E.M., Jacobs L.W., Sarett H.P. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis. 1964; 90: 721–729.</mixed-citation><mixed-citation xml:lang="en">Sheffner A.L., Medler E.M., Jacobs L.W., Sarett H.P. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis. 1964; 90: 721–729.</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Boman G., Bäcker U., Larsson S. et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. J. Respir. Dis. 1983; 64 (6): 405–415.</mixed-citation><mixed-citation xml:lang="en">Boman G., Bäcker U., Larsson S. et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. J. Respir. Dis. 1983; 64 (6): 405–415.</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Grassi C., Morandini G.C. A controlled trial of intermittent oral acetylcysteine in the long"term treatment of chronic bronchitis. Eur. J. Clin. Pharmacol. 1976; 9 (5–6): 393–396.</mixed-citation><mixed-citation xml:lang="en">Grassi C., Morandini G.C. A controlled trial of intermittent oral acetylcysteine in the long"term treatment of chronic bronchitis. Eur. J. Clin. Pharmacol. 1976; 9 (5–6): 393–396.</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Hansen N.C., Skriver A., Brorsen"Riis L. et al. Orally administered N"acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535.</mixed-citation><mixed-citation xml:lang="en">Hansen N.C., Skriver A., Brorsen"Riis L. et al. Orally administered N"acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535.</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Pela R., Calcagni A.M., Subiaco S. et al. N"acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999; 66 (6): 495–500.</mixed-citation><mixed-citation xml:lang="en">Pela R., Calcagni A.M., Subiaco S. et al. N"acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999; 66 (6): 495–500.</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N"acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, doubleblind placebo"controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194.</mixed-citation><mixed-citation xml:lang="en">Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N"acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, doubleblind placebo"controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194.</mixed-citation></citation-alternatives></ref><ref id="cit243"><label>243</label><citation-alternatives><mixed-citation xml:lang="ru">British Thoracic Society Research Committee. Oral N"acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985; 40 (11): 832–835.</mixed-citation><mixed-citation xml:lang="en">British Thoracic Society Research Committee. Oral N"acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985; 40 (11): 832–835.</mixed-citation></citation-alternatives></ref><ref id="cit244"><label>244</label><citation-alternatives><mixed-citation xml:lang="ru">Decramer M., Rutten"van Mölken M., Dekhuijzen P.N. et al. Effects of N"acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost"Utility Study, BRONCUS): a randomised placebo"controlled trial. Lancet. 2005; 365 (9470): 1552–1560.</mixed-citation><mixed-citation xml:lang="en">Decramer M., Rutten"van Mölken M., Dekhuijzen P.N. et al. Effects of N"acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost"Utility Study, BRONCUS): a randomised placebo"controlled trial. Lancet. 2005; 365 (9470): 1552–1560.</mixed-citation></citation-alternatives></ref><ref id="cit245"><label>245</label><citation-alternatives><mixed-citation xml:lang="ru">Dueholm M., Nielsen C., Thorshauge H. et al. N"acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi"centre study. Respir. Med. 1992; 86 (2): 89–92.</mixed-citation><mixed-citation xml:lang="en">Dueholm M., Nielsen C., Thorshauge H. et al. N"acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi"centre study. Respir. Med. 1992; 86 (2): 89–92.</mixed-citation></citation-alternatives></ref><ref id="cit246"><label>246</label><citation-alternatives><mixed-citation xml:lang="ru">Parr G.D., Huitson A. Oral Fabrol (oral N"acetyl"cysteine) in chronic bronchitis. Br. J. Dis. Chest. 1987; 81 (4):341–348.</mixed-citation><mixed-citation xml:lang="en">Parr G.D., Huitson A. Oral Fabrol (oral N"acetyl"cysteine) in chronic bronchitis. Br. J. Dis. Chest. 1987; 81 (4):341–348.</mixed-citation></citation-alternatives></ref><ref id="cit247"><label>247</label><citation-alternatives><mixed-citation xml:lang="ru">Rasmussen J.B., Glennow C. Reduction in days of illness aft erlongterm treatment with N"acetylcysteine controlled"release tablets in patients with chronic bronchitis. Eur. Respir. J. 1988; 1 (4): 351–355.</mixed-citation><mixed-citation xml:lang="en">Rasmussen J.B., Glennow C. Reduction in days of illness aft erlongterm treatment with N"acetylcysteine controlled"release tablets in patients with chronic bronchitis. Eur. Respir. J. 1988; 1 (4): 351–355.</mixed-citation></citation-alternatives></ref><ref id="cit248"><label>248</label><citation-alternatives><mixed-citation xml:lang="ru">Schermer T., Chavannes N., Dekhuijzen R. et al. Fluticasone and N"acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103 (4): 542–551.</mixed-citation><mixed-citation xml:lang="en">Schermer T., Chavannes N., Dekhuijzen R. et al. Fluticasone and N"acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103 (4): 542–551.</mixed-citation></citation-alternatives></ref><ref id="cit249"><label>249</label><citation-alternatives><mixed-citation xml:lang="ru">Moretti M., Bottrighi P., Dallari R. et al. The effect of long"term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp. Clin. Res. 2004; 30 (4): 143–152.</mixed-citation><mixed-citation xml:lang="en">Moretti M., Bottrighi P., Dallari R. et al. The effect of long"term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp. Clin. Res. 2004; 30 (4): 143–152.</mixed-citation></citation-alternatives></ref><ref id="cit250"><label>250</label><citation-alternatives><mixed-citation xml:lang="ru">Braga P.C., Allegra L., Rampoldi C. et al. Longlasting effects on rheology and clearance of bronchial mucus aft ershort"term administration of high doses of carbocysteine"lysine to patients with chronic bronchitis. Respiration. 1990; 57 (6): 353–358.</mixed-citation><mixed-citation xml:lang="en">Braga P.C., Allegra L., Rampoldi C. et al. Longlasting effects on rheology and clearance of bronchial mucus aft ershort"term administration of high doses of carbocysteine"lysine to patients with chronic bronchitis. Respiration. 1990; 57 (6): 353–358.</mixed-citation></citation-alternatives></ref><ref id="cit251"><label>251</label><citation-alternatives><mixed-citation xml:lang="ru">Allegra L., Cordaro C.I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, doubleblind, placebo"controlled trial. Respiration. 1996; 63 (3): 174–180.</mixed-citation><mixed-citation xml:lang="en">Allegra L., Cordaro C.I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, doubleblind, placebo"controlled trial. Respiration. 1996; 63 (3): 174–180.</mixed-citation></citation-alternatives></ref><ref id="cit252"><label>252</label><citation-alternatives><mixed-citation xml:lang="ru">Grillage M., Barnard"Jones K. Long"term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br. J. Clin. Pract. 1985; 39 (10): 395–398.</mixed-citation><mixed-citation xml:lang="en">Grillage M., Barnard"Jones K. Long"term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br. J. Clin. Pract. 1985; 39 (10): 395–398.</mixed-citation></citation-alternatives></ref><ref id="cit253"><label>253</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet. 2008; 371 (9629): 2013– 2018.</mixed-citation><mixed-citation xml:lang="en">Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet. 2008; 371 (9629): 2013– 2018.</mixed-citation></citation-alternatives></ref><ref id="cit254"><label>254</label><citation-alternatives><mixed-citation xml:lang="ru">Bartziokas K., Papaioannou A.I., Minas M. et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm. harmacol. Ther. 2011; 24 (5): 625–631.</mixed-citation><mixed-citation xml:lang="en">Bartziokas K., Papaioannou A.I., Minas M. et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm. harmacol. Ther. 2011; 24 (5): 625–631.</mixed-citation></citation-alternatives></ref><ref id="cit255"><label>255</label><citation-alternatives><mixed-citation xml:lang="ru">Blamoun A.I., Batty G.N., DeBari V.A. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008; 62 (9): 1373–1378.</mixed-citation><mixed-citation xml:lang="en">Blamoun A.I., Batty G.N., DeBari V.A. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int. J. Clin. Pract. 2008; 62 (9): 1373–1378.</mixed-citation></citation-alternatives></ref><ref id="cit256"><label>256</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C.C., Chan W.L., Chen Y.C. et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population"based cohort study in Taiwan. Clin. Ther. 2011; 33 (10): 1365– 1370.</mixed-citation><mixed-citation xml:lang="en">Huang C.C., Chan W.L., Chen Y.C. et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population"based cohort study in Taiwan. Clin. Ther. 2011; 33 (10): 1365– 1370.</mixed-citation></citation-alternatives></ref><ref id="cit257"><label>257</label><citation-alternatives><mixed-citation xml:lang="ru">Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin"converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47 (12): 2554–2560.</mixed-citation><mixed-citation xml:lang="en">Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin"converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47 (12): 2554–2560.</mixed-citation></citation-alternatives></ref><ref id="cit258"><label>258</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M.T., Lo Y.W., Tsai C.L. et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 2013; 126 (7): 598–606.</mixed-citation><mixed-citation xml:lang="en">Wang M.T., Lo Y.W., Tsai C.L. et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 2013; 126 (7): 598–606.</mixed-citation></citation-alternatives></ref><ref id="cit259"><label>259</label><citation-alternatives><mixed-citation xml:lang="ru">Criner G.J., Connett J.E., Aaron S.D. et al. COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate"to"severe COPD. N. Engl. J. Med. 2014; 370 (23): 2201–2210.</mixed-citation><mixed-citation xml:lang="en">Criner G.J., Connett J.E., Aaron S.D. et al. COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate"to"severe COPD. N. Engl. J. Med. 2014; 370 (23): 2201–2210.</mixed-citation></citation-alternatives></ref><ref id="cit260"><label>260</label><citation-alternatives><mixed-citation xml:lang="ru">Casarosa P., Kollak I., Kiechle T. et al. Functional and biochemical rationales for the 24"hour"long duration of action of olodaterol. J. Pharmacol. Exp. Ther. 2011; 337 (3): 600–609.</mixed-citation><mixed-citation xml:lang="en">Casarosa P., Kollak I., Kiechle T. et al. Functional and biochemical rationales for the 24"hour"long duration of action of olodaterol. J. Pharmacol. Exp. Ther. 2011; 337 (3): 600–609.</mixed-citation></citation-alternatives></ref><ref id="cit261"><label>261</label><citation-alternatives><mixed-citation xml:lang="ru">van Noord J.A., Smeets J.J., Drenth B.M. et al. 24"hour bronchodilation following a single dose of the novel β"2"agonist olodaterol in COPD. Pulm. Pharmacol. Ther. 2011; 24 (6): 666–672.</mixed-citation><mixed-citation xml:lang="en">van Noord J.A., Smeets J.J., Drenth B.M. et al. 24"hour bronchodilation following a single dose of the novel β"2"agonist olodaterol in COPD. Pulm. Pharmacol. Ther. 2011; 24 (6): 666–672.</mixed-citation></citation-alternatives></ref><ref id="cit262"><label>262</label><citation-alternatives><mixed-citation xml:lang="ru">Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494.</mixed-citation><mixed-citation xml:lang="en">Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494.</mixed-citation></citation-alternatives></ref><ref id="cit263"><label>263</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Calzetta L., Matera M.G. β"2"adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 2011; 163 (1): 4–17.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Calzetta L., Matera M.G. β"2"adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 2011; 163 (1): 4–17.</mixed-citation></citation-alternatives></ref><ref id="cit264"><label>264</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34 (3): 757–769.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Matera M.G. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 2009; 34 (3): 757–769.</mixed-citation></citation-alternatives></ref><ref id="cit265"><label>265</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Molimard M. The scientifi c rationale for combining long"acting beta2"agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Molimard M. The scientifi c rationale for combining long"acting beta2"agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.</mixed-citation></citation-alternatives></ref><ref id="cit266"><label>266</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Rogliani P., Matera M.G. Aclidinium bromide/formoterol fumarate fixed"dose combination for thetreatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2013; 14 (6): 775–781.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Rogliani P., Matera M.G. Aclidinium bromide/formoterol fumarate fixed"dose combination for thetreatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2013; 14 (6): 775–781.</mixed-citation></citation-alternatives></ref><ref id="cit267"><label>267</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Rogliani P., Segreti A., Matera M.G. An update on bronchodilators in phase I and II clinical trials. Exp. Opin. Invest. Drugs. 2012; 21 (10): 1489–1501.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Rogliani P., Segreti A., Matera M.G. An update on bronchodilators in phase I and II clinical trials. Exp. Opin. Invest. Drugs. 2012; 21 (10): 1489–1501.</mixed-citation></citation-alternatives></ref><ref id="cit268"><label>268</label><citation-alternatives><mixed-citation xml:lang="ru">Dahl R., Chapman K.R., Rudolf M. et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 2013; 107 (10): 1558–1567.</mixed-citation><mixed-citation xml:lang="en">Dahl R., Chapman K.R., Rudolf M. et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 2013; 107 (10): 1558–1567.</mixed-citation></citation-alternatives></ref><ref id="cit269"><label>269</label><citation-alternatives><mixed-citation xml:lang="ru">Mak G., Hanania N.A. New bronchodilators. Curr. Opin. Pharmacol. 2012; 12 (3): 238–245.</mixed-citation><mixed-citation xml:lang="en">Mak G., Hanania N.A. New bronchodilators. Curr. Opin. Pharmacol. 2012; 12 (3): 238–245.</mixed-citation></citation-alternatives></ref><ref id="cit270"><label>270</label><citation-alternatives><mixed-citation xml:lang="ru">Matera M.G., Calzetta L., Segreti A., Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. Exp. Opin. Emerg. Drugs. 2012; 17 (1): 61–82.</mixed-citation><mixed-citation xml:lang="en">Matera M.G., Calzetta L., Segreti A., Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. Exp. Opin. Emerg. Drugs. 2012; 17 (1): 61–82.</mixed-citation></citation-alternatives></ref><ref id="cit271"><label>271</label><citation-alternatives><mixed-citation xml:lang="ru">Matera M.G., Page C.P., Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 2011; 32 (8): 495–506.</mixed-citation><mixed-citation xml:lang="en">Matera M.G., Page C.P., Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 2011; 32 (8): 495–506.</mixed-citation></citation-alternatives></ref><ref id="cit272"><label>272</label><citation-alternatives><mixed-citation xml:lang="ru">Van de Maele B., Fabbri L.M., Martin C. et al. Cardiovascular safety of QVA149, a combination of Indacateroland NVA237, in COPD patients. COPD. 2010; 7 (6): 418–427.</mixed-citation><mixed-citation xml:lang="en">Van de Maele B., Fabbri L.M., Martin C. et al. Cardiovascular safety of QVA149, a combination of Indacateroland NVA237, in COPD patients. COPD. 2010; 7 (6): 418–427.</mixed-citation></citation-alternatives></ref><ref id="cit273"><label>273</label><citation-alternatives><mixed-citation xml:lang="ru">van Noord J.A., Buhl R., Laforce C. et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65 (12): 1086–1091.</mixed-citation><mixed-citation xml:lang="en">van Noord J.A., Buhl R., Laforce C. et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65 (12): 1086–1091.</mixed-citation></citation-alternatives></ref><ref id="cit274"><label>274</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once"daily QVA149 compared with twicedaily salmeterolfluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double"blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.</mixed-citation><mixed-citation xml:lang="en">Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once"daily QVA149 compared with twicedaily salmeterolfluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double"blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.</mixed-citation></citation-alternatives></ref><ref id="cit275"><label>275</label><citation-alternatives><mixed-citation xml:lang="ru">Donohue J.F., Maleki"Yazdi M.R., Kilbride S. et al. Efficacy and safety of once"daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.</mixed-citation><mixed-citation xml:lang="en">Donohue J.F., Maleki"Yazdi M.R., Kilbride S. et al. Efficacy and safety of once"daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.</mixed-citation></citation-alternatives></ref><ref id="cit276"><label>276</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman G., Walker R.R., Brooks J. et al. 28"day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo"controlled trial. Pulm. Pharmacol. Ther. 2012; 25 (6): 465–471.</mixed-citation><mixed-citation xml:lang="en">Feldman G., Walker R.R., Brooks J. et al. 28"day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo"controlled trial. Pulm. Pharmacol. Ther. 2012; 25 (6): 465–471.</mixed-citation></citation-alternatives></ref><ref id="cit277"><label>277</label><citation-alternatives><mixed-citation xml:lang="ru">Kelleher D.L., Mehta R.S., Jean"Francois B.M. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012; 7 (12): e50716.</mixed-citation><mixed-citation xml:lang="en">Kelleher D.L., Mehta R.S., Jean"Francois B.M. et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012; 7 (12): e50716.</mixed-citation></citation-alternatives></ref><ref id="cit278"><label>278</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta R., Kelleher D., Preece A. et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open"label study. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 159–167.</mixed-citation><mixed-citation xml:lang="en">Mehta R., Kelleher D., Preece A. et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open"label study. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 159–167.</mixed-citation></citation-alternatives></ref><ref id="cit279"><label>279</label><citation-alternatives><mixed-citation xml:lang="ru">Lötvall J., Bakke P.S., Bjermer L. et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo"controlled randomised trial. Br. Med. J. Open. 2012; 2 (1): e000370.</mixed-citation><mixed-citation xml:lang="en">Lötvall J., Bakke P.S., Bjermer L. et al. Efficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo"controlled randomised trial. Br. Med. J. Open. 2012; 2 (1): e000370.</mixed-citation></citation-alternatives></ref><ref id="cit280"><label>280</label><citation-alternatives><mixed-citation xml:lang="ru">Traynor K. Fluticasone"vilanterol combination approved for COPD. Am. J. Health Syst. Pharm. 2013; 70 (12): 1008.</mixed-citation><mixed-citation xml:lang="en">Traynor K. Fluticasone"vilanterol combination approved for COPD. Am. J. Health Syst. Pharm. 2013; 70 (12): 1008.</mixed-citation></citation-alternatives></ref><ref id="cit281"><label>281</label><citation-alternatives><mixed-citation xml:lang="ru">Vestbo J., Anderson J., Brook R.D. et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur. Respir. J. 2013; 41 (5): 1017–1022.</mixed-citation><mixed-citation xml:lang="en">Vestbo J., Anderson J., Brook R.D. et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur. Respir. J. 2013; 41 (5): 1017–1022.</mixed-citation></citation-alternatives></ref><ref id="cit282"><label>282</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J. New therapies for chronic obstructive pulmonary disease. Med. Princ. Pract. 2010; 19 (5): 330–338.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J. New therapies for chronic obstructive pulmonary disease. Med. Princ. Pract. 2010; 19 (5): 330–338.</mixed-citation></citation-alternatives></ref><ref id="cit283"><label>283</label><citation-alternatives><mixed-citation xml:lang="ru">Barnes P.J. Development of new drugs for COPD. Curr. Med. Chem. 2013; 20 (12): 1531–1540.</mixed-citation><mixed-citation xml:lang="en">Barnes P.J. Development of new drugs for COPD. Curr. Med. Chem. 2013; 20 (12): 1531–1540.</mixed-citation></citation-alternatives></ref><ref id="cit284"><label>284</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Ciaprini C., Page C.P, Matera M.G. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Ther. Targets. 2007; 11 (10): 1273–1286.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Ciaprini C., Page C.P, Matera M.G. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Ther. Targets. 2007; 11 (10): 1273–1286.</mixed-citation></citation-alternatives></ref><ref id="cit285"><label>285</label><citation-alternatives><mixed-citation xml:lang="ru">Cazzola M., Page C.P., Calzetta L., Matera M.G. Emerging antiinflammatory strategies for COPD. Eur. Respir. J.2012; 40 (3): 724–741.</mixed-citation><mixed-citation xml:lang="en">Cazzola M., Page C.P., Calzetta L., Matera M.G. Emerging antiinflammatory strategies for COPD. Eur. Respir. J.2012; 40 (3): 724–741.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
